A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTINO), in Patients With Advanced Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2011
At a glance
- Drugs Cediranib (Primary) ; Ketoconazole
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 09 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Mar 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 21 Sep 2010 Planned end date changed from 1 Aug 2010 to 1 May 2011 as reported by ClinicalTrials.gov.